MedDataX Logo

The Efficacy & Safety of the UAS Immunotherapy Protocol

NCT ID: NCT01699659

Last Updated: 2012-10-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-04-30

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hypothesis: The UAS Immunotherapy protocol is efficacious and at least as efficacious as protocols described in the Allergy literature.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients will be assessed for efficacy of the immunotherapy protocol by completing Consented-IRB approved clinical, medication, quality of life survey questions comparing current status while on therapy in contrast to 12 months before the inception of therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Perennial Allergic Rhinitis With Seasonal Variation

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Allergic Rhinitis Allergen Immunotherapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

allergen immunotherapy

allergy shots

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

allergy shots

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Allergic rhinitis between 18 and 65 years old who have chosen to undergo immunotherapy.

Exclusion Criteria

* No beta blocker use,
* no pregnancy,
* no systemic steroids,
* no severe asthma/copd,
* no severe collagen vascular disorders,
* no neoplastic or uncontrolled seizure activity,
* no previous anaphylaxis, no significant cardiovsacular disease.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

United Allergy Services

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Frederick M. Schaffer, MD

Chief Medical Officer

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Frederick M Schaffer, M.D.

Role: PRINCIPAL_INVESTIGATOR

United Allergy Services

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UAS

San Antonio, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UAS protocol #1

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

UAS protocol #1

Identifier Type: -

Identifier Source: org_study_id